Semorinemab, a monoclonal antibody that targets all six isoforms of tau at the N-terminus, both monomeric and oligomeric, phosphorylated or not, was tested in two phase II trials on prodromal to mild AD (TAURIET, currently completed) and moderate AD (LAURIET, currently active, not recruiting). This evidence concerns the gene MAPT and Alzheimer disease.